Insider Buying Sparks Interest: Recent discussions on X about Biohaven Ltd. (BHVN) have centered on significant insider buying activity. Posts highlight that the CEO and a director purchased millions in shares, which has led to a notable uptick in stock price.
Public Offering Concerns: Another hot topic on X is Biohaven’s recent $175 million public offering priced at $7.50 per share. Many users express concern over potential dilution, especially given the stock’s low trading levels. Some question the timing, suggesting the company may be in urgent need of cash.
Mixed Reactions to News: Conversations also touch on an FDA setback, with a major bank slashing its price target for BHVN. Despite this, a few users remain optimistic due to insider confidence, while others caution about ongoing risks.
Note: This discussion summary was generated from an AI condensation of post data.
Biohaven Ltd. Insider Trading Activity
Biohaven Ltd. insiders have traded $BHVN stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BHVN stock by insiders over the last 6 months:
- JOHN W CHILDS purchased 3,333,333 shares for an estimated $24,999,997
- VLAD CORIC (Chief Executive Officer) has made 2 purchases buying 666,666 shares for an estimated $4,999,995 and 0 sales.
- GREGORY BAILEY purchased 400,000 shares for an estimated $3,000,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Biohaven Ltd. Hedge Fund Activity
We have seen 136 institutional investors add shares of Biohaven Ltd. stock to their portfolio, and 143 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 6,374,407 shares (-68.9%) from their portfolio in Q3 2025, for an estimated $95,679,849
- FARALLON CAPITAL MANAGEMENT LLC removed 4,813,167 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $67,913,786
- ARMISTICE CAPITAL, LLC removed 2,136,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $32,061,360
- JANUS HENDERSON GROUP PLC added 1,718,585 shares (+34.0%) to their portfolio in Q3 2025, for an estimated $25,795,960
- VOLORIDGE INVESTMENT MANAGEMENT, LLC removed 1,285,482 shares (-89.3%) from their portfolio in Q3 2025, for an estimated $19,295,084
- JPMORGAN CHASE & CO removed 1,236,587 shares (-48.1%) from their portfolio in Q3 2025, for an estimated $18,561,170
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,161,624 shares (-36.6%) from their portfolio in Q3 2025, for an estimated $17,435,976
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Biohaven Ltd. Analyst Ratings
Wall Street analysts have issued reports on $BHVN in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 11/13/2025
- BTIG issued a "Buy" rating on 11/06/2025
- TD Cowen issued a "Buy" rating on 11/05/2025
- UBS issued a "Buy" rating on 09/16/2025
- Raymond James issued a "Strong Buy" rating on 09/03/2025
- B of A Securities issued a "Buy" rating on 08/12/2025
- Baird issued a "Outperform" rating on 08/12/2025
To track analyst ratings and price targets for Biohaven Ltd., check out Quiver Quantitative's $BHVN forecast page.
Biohaven Ltd. Price Targets
Multiple analysts have issued price targets for $BHVN recently. We have seen 13 analysts offer price targets for $BHVN in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Samantha Semenkow from Citigroup set a target price of $14.0 on 11/13/2025
- Thomas Shrader from BTIG set a target price of $16.0 on 11/06/2025
- Leonid Timashev from RBC Capital set a target price of $9.0 on 11/06/2025
- William Pickering from Bernstein set a target price of $9.0 on 11/06/2025
- Tyler Van Buren from TD Cowen set a target price of $15.0 on 11/05/2025
- Ashwani Verma from UBS set a target price of $26.0 on 09/16/2025
- Chris Raymond from Raymond James set a target price of $75.0 on 09/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
